In a report released yesterday, Faisal Khurshid from Leerink Partners reiterated a Buy rating on Kymera Therapeutics (KYMR – Research ...
Leerink Partners analyst Jonathan Chang maintained a Buy rating on Molecular Partners (MOLN – Research Report) on October 22. The ...
Fintel reports that on October 24, 2024, Leerink Partners initiated coverage of Tenax Therapeutics (NasdaqCM:TENX) with a ...
The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...
Leerink Partners' affiliate, MEDACorp, announced today the launch of a new division, the Center for Pharmacoeconomics (CPE), which will be dedicated to advancing the understanding of the societal ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company ...
Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 12.84% ...
On Thursday, Progyny Inc (PGNY) stock saw a decline, ending the day at $15.55 which represents a decrease of $-0.31 or -1.95% from the prior close of $15.86. The stock opened at $15.84 and touched a ...
Leerink Partners maintained their Outperform rating on Roivant Sciences (NASDAQ:ROIV) with a steady price target of $17.00. The firm's analyst highlighted Roivant's executive incentive compensation ...
Leerink Partners maintained their Outperform rating on Roivant Sciences (NASDAQ:ROIV) with a steady price target of $17.00. The firm's analyst highlighted Roivant's executive incentive ...
On Monday, Leerink Partners adjusted their outlook on Elevance Health Inc (NYSE:ELV) shares, reducing the price target to $515 from the previous $620, while retaining an Outperform rating on the ...